AI-Driven Prediction of Hospital-Acquired Infections With EHR
Condition(s) studied
Investigational drug(s) / intervention(s)
AI-Based Diagnostic and Prognostic Model: This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, clinical observations, and treatment data, to predict the risk of hospital-acquired infections (HAIs). The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of patients at risk for infections. By analyzing historical health data, the model aims to predict potential infection developments, improving early detection, prevention strategies, and patient outcomes in hospital settings.
Study summary
This is a multi-center, clinical study designed to evaluate the application and effectiveness of an AI-assisted predictive model for identifying and diagnosing infection, leveraging multimodal health data.
Eligibility
Primary outcome measure(s)
- Area Under the Curve (AUC) — 1 year
AUC of the ROC curve, used to quantify diagnostic accuracy. No unit (a ratio or percentage, typically expressed as a number between 0 and 1). - F1 Score — 1 year
The F1 score is the harmonic mean of precision and sensitivity (recall). It is a good measure of the model's ability to identify both true positives and minimize false positives, especially in cases where the classes are imbalanced (e.g., when the number of healthy cases is much higher than disease cases). The F1 score ranges from 0 to 1, with 1 indicating perfect precision and recall.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| First Affiliated Hospital of Wenzhou Medical University | Wenzhou | Zhejiang | Recruiting |
| Second Affiliated Hospital of Wenzhou Medical University | Wenzhou | Zhejiang | Recruiting |
More The Eye Hospital of Wenzhou Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06791382 on ClinicalTrials.gov ↗ ← All trials in China